I read with great interest the article by Cosci et al in a recent issue of your journal.[@b1-prbm-5-047] The article provides for highly interesting reading and is very thought-provoking. Interestingly, the past few years have seen the emergence of extensive data that establish a close association between the A118G single nucleotide polymorphism of the OPRM1 gene and opioid, alcohol, and nicotine dependence.

A higher threshold to pain has been observed in individuals with the A118G variant.[@b2-prbm-5-047] Not surprisingly, Tan et al and Kapur et al have demonstrated a close association between the A118G variant and heroin dependence.[@b3-prbm-5-047],[@b4-prbm-5-047] Altered modulation of protein kinase A is responsible for this close association between the A118G variant of the OPRM1 gene and heroin dependency.[@b5-prbm-5-047] A recent Japanese study has demonstrated that the presence of the A118G polymorphism is associated with an increased risk of addiction to alcohol.[@b6-prbm-5-047] Similarly, a recent Swedish study has demonstrated that the A118G variant is associated with an 11% risk of ethanol dependency.[@b7-prbm-5-047] The treatment response to naltrexone in individuals with alcohol dependency varies greatly, depending on the presence or absence of the A118G variant.[@b8-prbm-5-047] In females, there is a strong association between nicotine reinforcement and the A118G haplotype.[@b9-prbm-5-047]

The above examples illustrate a close association between A118G polymorphism and drug dependence. Hopefully, the coming years will see increased clinical application of this close association in identifying and effectively treating individuals with this polymorphism.
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We thank Dr Kapoor for appreciating our review on nicotine dependence and psychological distress, and having taken it as a cue to reflect on the possible association between the A118G single nucleotide polymorphism of the OPRM1 gene and drug dependence. The literature offers several sets of data on this issue but, unfortunately, only a small number of studies have focused on nicotine dependence. For instant, Ray et al recently noted that human mu opioid receptor (OPRM1 A118G) polymorphism is associated with brain μ opioid receptor binding in smokers.[@b1-prbm-5-049] Further, Falcone et al found increased availability of the μ opioid receptor in the amygdala of smokers that could be contributory, emphasizing the motivation to smoke to obtain negative affective relief.[@b2-prbm-5-049]

Of course, we really hope that future investigations will clarify the possible association between smoking and genes, and as a further step, lead to the development of novel therapeutics. However, it is noteworthy that we are constantly reminded that genetics will transform and improve our practice, but nothing has really come in the past two decades.[@b3-prbm-5-049],[@b4-prbm-5-049] Thus, psychopathology[@b5-prbm-5-049] and clinical judgment,[@b6-prbm-5-049] still underappreciated as scientific tools but commonly used in clinical practice, can be a valid alternative approach to make the correct diagnosis and choose a tailored treatment for drug dependence, in particular for nicotine dependence. Indeed, good organization of clinical information (encompassing, eg, psychological distress and psychological well being), the use of a transfer station with repeated evaluations instead of diagnostic endpoints,[@b7-prbm-5-049] and staging methods[@b8-prbm-5-049] may guide assessment, treatment choice, and planning of follow-up visits or interventions.[@b7-prbm-5-049]
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